[go: up one dir, main page]

IN2013CN00297A - - Google Patents

Info

Publication number
IN2013CN00297A
IN2013CN00297A IN297CHN2013A IN2013CN00297A IN 2013CN00297 A IN2013CN00297 A IN 2013CN00297A IN 297CHN2013 A IN297CHN2013 A IN 297CHN2013A IN 2013CN00297 A IN2013CN00297 A IN 2013CN00297A
Authority
IN
India
Prior art keywords
biomarkers
proteome
subject
amount
additional
Prior art date
Application number
Other languages
English (en)
Inventor
Carl Arne Krister Borrebaeck
Christer Lars Bertil Wingren
Original Assignee
Immunovia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovia Ab filed Critical Immunovia Ab
Publication of IN2013CN00297A publication Critical patent/IN2013CN00297A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IN297CHN2013 2010-06-11 2011-06-09 IN2013CN00297A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1009798.8A GB201009798D0 (en) 2010-06-11 2010-06-11 Method,array and use thereof
PCT/GB2011/000865 WO2011154698A2 (fr) 2010-06-11 2011-06-09 Procédé, groupement, et leur utilisation

Publications (1)

Publication Number Publication Date
IN2013CN00297A true IN2013CN00297A (fr) 2015-07-03

Family

ID=42471508

Family Applications (1)

Application Number Title Priority Date Filing Date
IN297CHN2013 IN2013CN00297A (fr) 2010-06-11 2011-06-09

Country Status (11)

Country Link
US (2) US20130143760A1 (fr)
EP (1) EP2580592B1 (fr)
JP (1) JP6104796B2 (fr)
CN (1) CN103038642B (fr)
AU (1) AU2011263533B2 (fr)
BR (1) BR112012031444A2 (fr)
CA (1) CA2801863A1 (fr)
ES (1) ES2608956T3 (fr)
GB (1) GB201009798D0 (fr)
IN (1) IN2013CN00297A (fr)
WO (1) WO2011154698A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201009798D0 (en) 2010-06-11 2010-07-21 Immunovia Ab Method,array and use thereof
US10928402B2 (en) 2012-12-28 2021-02-23 Nx Prenatal Inc. Treatment of spontaneous preterm birth
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
EP3825418A3 (fr) * 2014-05-22 2021-09-15 The Scripps Research Institute Signatures moléculaires pour distinguer des rejets de greffe hépatique ou des lésions hépatiques
EP3210144B1 (fr) * 2014-10-24 2020-10-21 Koninklijke Philips N.V. Pronostic médical et prédiction de réponse de traitement utilisant de activités de voies de signalisation cellulaire multiples
JP6718465B2 (ja) * 2015-02-18 2020-07-08 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドＳｉｅｍｅｎｓ Ｈｅａｌｔｈｃａｒｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｉｎｃ． 視覚システムにおけるトレイスロットタイプ及びチューブタイプの位置ベース検出
TWI582240B (zh) * 2015-05-19 2017-05-11 鄭鴻鈞 以基因體預後評估試劑組預測乳癌患者局部區域復發風險及放射治療有效性的方法、用途及裝置
EP3384076A4 (fr) * 2015-12-04 2019-09-25 Nx Prenatal Inc. Utilisation de microparticules en circulation pour stratifier le risque d'accouchement prématuré spontané
CN109444402B (zh) * 2018-12-18 2021-05-28 郑州安图生物工程股份有限公司 去甲肾上腺素发光免疫检测试剂盒

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3169789D1 (en) 1980-05-02 1985-05-15 Edward P Davis Leg aid device
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US5376531A (en) 1992-09-03 1994-12-27 Northwestern University Method of detecting cancer
US5856090A (en) 1994-09-09 1999-01-05 The Scripps Research Institute DNA-methylase linking reaction
CN1211279A (zh) 1996-01-10 1999-03-17 科里克萨有限公司 用于治疗和诊断乳腺癌的组合物和方法
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
RO114835B1 (ro) * 1997-03-17 1999-07-30 Ioan Puşcaş Metodă rapidă de diagnostic al cancerelor
US6190857B1 (en) 1997-03-24 2001-02-20 Urocor, Inc. Diagnosis of disease state using MRNA profiles in peripheral leukocytes
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US6492505B1 (en) 1999-02-01 2002-12-10 Incyte Genomics, Inc. Composition for detection of genes encoding membrane-associated proteins
US20030138793A1 (en) 2001-06-10 2003-07-24 Irm Llc, A Delaware Limited Liability Company Molecular signatures of commonly fatal carcinomas
WO2004037996A2 (fr) 2002-10-24 2004-05-06 Duke University Evaluation des etats relatifs au cancer du sein et des resultats a l'aide de profils d'expression genique
US20040087571A1 (en) 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
US20040259161A1 (en) 2003-03-12 2004-12-23 Fredrik Nilsson Screening assay
KR20060013425A (ko) 2003-05-29 2006-02-09 밀레니엄 파머슈티컬스 인코퍼레이티드 유방암의 확인, 평가, 예방 및 요법에 대한 조성물, 키트및 방법
JP2007516693A (ja) 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 癌の治療および診断のための組成物および方法
EP2280285A1 (fr) * 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Procédé d'utilisation de dosages de cytokine pour diagnostiquer, traiter et évaluer des maladies inflammatoires et auto-immunes
ES2377407T3 (es) 2003-10-15 2012-03-27 F. Hoffmann-La Roche Ag Utilización de la proteína ASC como marcador para cáncer de seno
WO2005080570A1 (fr) 2004-02-24 2005-09-01 Mitsubishi Rayon Co., Ltd. Gene relatif a l'estimatuon du pronostic postopératoire pour le cancer du poumon
WO2005107491A2 (fr) 2004-05-05 2005-11-17 Northeastern University Chromatographie d'affinite multi-lectine et ses utilisations
WO2006105642A1 (fr) 2005-04-05 2006-10-12 British Columbia Cancer Agency Marqueurs biologiques pour la detection du cancer du poumon et utilisations de ceux-ci
US20100173788A1 (en) 2005-06-21 2010-07-08 Vermillion, Inc. Biomarkers for breast cancer
WO2007022248A2 (fr) 2005-08-16 2007-02-22 Sloan Kettering Institute For Cancer Research Methodes de detection du cancer, dans lesquelles sont utilises des profils peptidiques
EP1777523A1 (fr) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode pour pronostiquer la progression d'un cancer et les résultats du patient et les moyens pour performer la méthode
US20080311601A1 (en) 2005-11-02 2008-12-18 Elting James J Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy
EP1971359A2 (fr) * 2005-12-16 2008-09-24 Electrophoretics Limited Diagnostic et pronostic de cancer colorectal
SG142186A1 (en) 2006-10-20 2008-05-28 Agency Science Tech & Res Breast tumour grading
WO2008117067A2 (fr) 2007-03-27 2008-10-02 Carl Arne Krister Borrebaeck Procédé, assemblage et utilisation de celui-ci
NZ562237A (en) 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
GB0723179D0 (en) 2007-11-27 2008-01-02 Immunovia Ab Diagnostic methods and arrays for use in the same
EP2269070A1 (fr) * 2008-03-14 2011-01-05 DNAR, Inc Protéines de réparation de l'adn associées à des cancers du sein triple négatifs et leurs procédés d'utilisation
EP2105740A1 (fr) * 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Biomarqueurs pour surveiller ou prédire le traitement du cancer
US8519116B2 (en) 2008-04-29 2013-08-27 Siemens Healthcare Diagnostics Inc. Method for predicting a clinical response of a patient suffering from or at risk of developing cancer towards a given mode of treatment
JP2010151800A (ja) 2008-11-06 2010-07-08 Kumamoto Univ 生活習慣病及び／又は癌の診断剤
WO2010076322A1 (fr) 2008-12-30 2010-07-08 Siemens Healthcare Diagnostics Inc. Prédiction de la réponse à une chimiothérapie à base de taxane/d'anthracycline lors d'un cancer du sein
CA2753971C (fr) 2009-01-28 2018-10-02 Steven Buechler Test de recidive a progression acceleree
EP4350001A3 (fr) 2009-11-23 2024-06-19 Genomic Health, Inc. Procédés destinés à prédire l'issue clinique d'un cancer
GB201009798D0 (en) 2010-06-11 2010-07-21 Immunovia Ab Method,array and use thereof
GB201410226D0 (en) 2014-06-09 2014-07-23 Immunovia Ab Methods and arrays for use in the same

Also Published As

Publication number Publication date
EP2580592A2 (fr) 2013-04-17
CN103038642B (zh) 2017-02-22
EP2580592B1 (fr) 2016-10-05
AU2011263533A8 (en) 2013-03-21
WO2011154698A2 (fr) 2011-12-15
ES2608956T3 (es) 2017-04-17
GB201009798D0 (en) 2010-07-21
JP2013529773A (ja) 2013-07-22
US20130143760A1 (en) 2013-06-06
WO2011154698A8 (fr) 2013-01-17
BR112012031444A2 (pt) 2016-10-25
AU2011263533B2 (en) 2016-11-03
US10564163B2 (en) 2020-02-18
CN103038642A (zh) 2013-04-10
JP6104796B2 (ja) 2017-03-29
US20180313852A1 (en) 2018-11-01
CA2801863A1 (fr) 2011-12-15
AU2011263533A1 (en) 2013-01-10
WO2011154698A3 (fr) 2012-03-01

Similar Documents

Publication Publication Date Title
IN2013CN00297A (fr)
MX363201B (es) Procedimiento, matriz y uso para determinar la presencia de cancer pancreatico.
IL252832B (en) Use of biomarkers to detect ovarian cancer
WO2005098447A3 (fr) Biomarqueurs du cancer de l'ovaire
JP2013529773A5 (fr)
CA2816991A1 (fr) Recepteur alpha de folate a titre de marqueur diagnostique et pronostique des cancers exprimant un recepteur alpha de folate
BR112012019542A2 (pt) "método para avaliar o estado renal em um indivíduo, medição de um ou mais biomarcadores, e, kit"
NZ629074A (en) Biomarkers for gastric cancer and uses thereof
ATE457362T1 (de) Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebs
NZ624816A (en) Ratio based biomarkers and methods of use thereof
WO2017050939A3 (fr) Méthode, ensemble et leur utilisation
MX2018013621A (es) Metodo, matriz y uso de estos.
WO2008128043A3 (fr) Procédés de diagnostic et de pronostic pour des carcinomes de cellules rénales
MX2019008911A (es) Metodos, matrices y usos de estos.
WO2015091575A3 (fr) Niveaux différents de marqueurs emt dans des échantillons de cellules sanguines pour le diagnostic du cancer, en particulier du cancer colorectal (crc) et du cancer pancréatique (pc)
MX2012007009A (es) Método para diagnosticar un tumor maligno.
EP3557259A3 (fr) Procédés et réseaux destinés à être utilisés avec ceux-ci
GB201206323D0 (en) Methods and arrays for use in the same
WO2005044794A3 (fr) Methodes immunohistochimiques
JP2015519043A5 (fr)
WO2017211893A8 (fr) Signatures de biomarqueur du lupus érythémateux systémique et leurs utilisations
Sawazaki et al. Increased nucleophosmin expression is a strong predictor of recurrence and prognosis in patients with N0M0 upper tract urothelial carcinoma undergoing radical nephroureterectomy
WO2013119279A3 (fr) Tests et procédés de diagnostic du cancer des ovaires
ATE393393T1 (de) Verwendung des proteins spee als marker für brustkrebs
KR102235718B9 (ko) 방광암 진단 또는 예후 분석용 바이오마커 조성물, 키트 및 이를 이용한 진단 방법